Skip to main content

Drug Safety

      RT @RHEUMarampa: Statin therapy may exacerbate underlying neuromuscular disorders.
      ‼️REMEMBER☝️The only ABSOLUT
      2 years 5 months ago
      Statin therapy may exacerbate underlying neuromuscular disorders. ‼️REMEMBER☝️The only ABSOLUTE contraindication to statins are pts who are HMGCR+ #ACR22 @RheumNow #acrreview https://t.co/A3XGHlrm0X
      PsA Cycling or Switching MOAs
      The RheumNow faculty reporters have been scouring the meeting and online presentations to find the best abstracts from ACR22. Here are some of their choice abstracts reported today on day 1 of…
      RT @RHEUMarampa: How long do we hold meds for live-attenuated #Vaccines? ACR 2022 vax guidelines:
      💉Pre-vax:
      💊csDMA
      2 years 5 months ago
      How long do we hold meds for live-attenuated #Vaccines? ACR 2022 vax guidelines: 💉Pre-vax: 💊csDMARDs - hold time 4 wks 💊bDMARDs -hold time of one dosing interval 💉Post-vax: hold DMARDs for 4 wks #ACR22 @rheumnow @rheumarhyme @doktora_ging https://t.co/MGc422EtIC
      RT @RichardPAConway: Patel @NaomiRheumMD et al. HbA1c in GiACTA. Tocilizumab assoc HbA1c reduction independent of steroi
      2 years 5 months ago
      Patel @NaomiRheumMD et al. HbA1c in GiACTA. Tocilizumab assoc HbA1c reduction independent of steroids. Daily steroid dose assoc HbA1c @rheumnow #ACR22 Abstr#0461 https://t.co/9Nbewrpww8 https://t.co/NyeTyWICF6
      RT @DrTrishHarkins: 🪞MIRROR RCT🪞

      💊MTX ⬆️ response of P
      2 years 5 months ago
      🪞MIRROR RCT🪞 💊MTX ⬆️ response of Pegloticase in resistant gout pts (60% vs PBO 30.8%) 🦶Tophus resolution wk 52 >24 (cont. benefit💪🏻) 🧪⬇️ drug Ab with MTX ✅ No new IRs Abst#0001 #ACR22 @RheumNow #plenary https://t.co/8lPKQ0VGqC
      RT @ericdeinmd: Ab0349 #ACR22 BEL vs AZA ifn risks in non-renal SLE
      BEL: lower risk of severe ifn (HR 0.81) and hospital
      2 years 5 months ago
      Ab0349 #ACR22 BEL vs AZA ifn risks in non-renal SLE BEL: lower risk of severe ifn (HR 0.81) and hospitalization for ifn (HR 0.73) through 5 yrs Challenge to interpret data as 56% of patients were on glucocorticoids and other anti-rheumatic meds @RheumNow https://t.co/a0tNFn5Wqr
      RT @uptoTate: MIRROR results showed 12-month safety/efficacy support MTX co-therapy w/ pegloticase. No IRs after 6mo of
      2 years 5 months ago
      MIRROR results showed 12-month safety/efficacy support MTX co-therapy w/ pegloticase. No IRs after 6mo of tx and increased resolution of tophi at wk 52. I use MTX in my gout pts on Pegloticase. Are you #rheumtwitter? Abs 0001 #ACR22 @RheumNow https://t.co/FLwOmAYrS4
      ×